Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00528333
Recruitment Status : Completed
First Posted : September 12, 2007
Last Update Posted : January 7, 2015
Sponsor:
Information provided by (Responsible Party):
Seagen Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : August 2010
Actual Study Completion Date : August 2010
Certification/Extension First Submitted : October 7, 2011